Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411379 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Sonelokimab
DRUG: Placebo

Sponsor

MoonLake Immunotherapeutics AG